Identification of Sequence Variations in the Apolipoprotein A2 Gene and Their Relationship with Serum High-Density Lipoprotein Cholesterol Levels

Fatemeh Bandarian¹², Maryam Sadat Daneshpour³, Mehdi Hedayati³, Mohsen Naseri⁴ and Fereidoun Azizi⁴

¹Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ²Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ³Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ⁴Genomic Research Center, Birjand University of Medical Sciences, Birjand, Iran

Received 29 November 2014; revised 19 April 2015; accepted 20 April 2015

ABSTRACT

Background: Apolipoprotein A2 (APOA2) is the second major apolipoprotein of the high-density lipoprotein cholesterol (HDL-C). The study aim was to identify APOA2 gene variation in individuals within two extreme tails of HDL-C levels and its relationship with HDL-C level. Methods: This cross-sectional survey was conducted on participants from Tehran Glucose and Lipid Study (TGLS) at Research Institute for Endocrine Sciences, Tehran, Iran from April 2012 to February 2013. In total, 79 individuals with extreme low HDL-C levels (≤5th percentile for age and gender) and 63 individuals with extreme high HDL-C levels (≥95th percentile for age and gender) were selected. Variants were identified using DNA amplification and direct sequencing. Results: Screen of all exons and the core promoter region of APOA2 gene identified nine single nucleotide substitutions and one microsatellite; five of which were known and four were new variants. Of these nine variants, two were common tag single nucleotide polymorphisms (SNPs) and seven were rare SNPs. Both exonic substitutions were missense mutations and caused an amino acid change. There was a significant association between the new missense mutation (variant Chr.1:16119226, Ala98Pro) and HDL-C level. Conclusion: None of two common tag SNPs of rs6413453 and rs5082 contributes to the HDL-C trait in Iranian population, but a new missense mutation in APOA2 in our population has a significant association with HDL-C.

Keywords: Apolipoprotein A-II, Hyperlipidemia, Polymorphism, Mutation, Genes

Corresponding Author: Fereidoun Azizi
Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Tel: (+98-21) 22432500; Fax: (+98-21) 22416264; E-mail: Azizi@endocrine.ac.ir

INTRODUCTION

Low high-density lipoprotein cholesterol (HDL-C) is a known risk factor of coronary artery disease (CAD) and a component of metabolic syndrome that increases the vulnerability to CAD[1]. The High prevalence of low HDL-C level has been reported in Iranian population[2]. Apolipoprotein A2 (APOA2) is the second major protein of the HDL-C particles and comprises about 20% of the total HDL-C protein content[3,4]. APOA2 has antagonist effect on cellular cholesterol efflux through the modulating of the enzymes activity in HDL-C remodeling, including lecithin-cholesterol acyltransferase, cholesteryl-ester transfer protein, hepatic lipase and inhibition of lipoprotein lipase[5,6]. APOA2 over-expression has been shown to increase the HDL-C level in animal models, but this elevation...
has no protective effect on CAD\cite{7}. Such evidence has not been observed in human studies. Furthermore, it has been suggested that the disorders of APOA2 metabolism could increase the risk of CAD by direct or indirect effects on serum lipids, insulin resistance, and atherosclerosis\cite{8}. APOA2, which is encoded by APOA2 gene containing three exons, has been located at chromosome 1q21-q23. The association of APOA2 variants with diabetes, obesity, and insulin resistance has been reported in the previous studies\cite{7,9,10}; nevertheless, no such an association has been found for the HDL-C level.

Because there is no data about the variants of APOA2 gene in Iranian populations with different ethnic groups, this study aimed to identify genetic variants in APOA2 gene and their association with HDL-C levels.

MATERIALS AND METHODS

Participants

The present cross-sectional study was conducted on individuals with extreme HDL-C levels. The patients were selected from the participants of Tehran Glucose and Lipid Study (TLGS) at Research Institute for Endocrine Sciences, Tehran, Iran from April 2012 to February 2013. TLGS, as a family-based cohort study with more than 15,005 participants investigates the cardiovascular risk factors and disease in the residents of Tehran district\cite{11}. All participants signed a written informed consent before enrollment, and the protocol of the study was approved by Ethics Committee at Research Institute for Endocrine Sciences at Shahid Beheshti University of Medical Sciences (Tehran, Iran). Those participants of TLGS aged between 15 and 70 years old were included in the present study. Among 10,764 individuals in these age ranges, those with extreme low HDL-C levels (≤5th percentile for age and gender) and those with extreme high HDL-C levels (≥95th percentile for age and gender) were selected. In addition, the individuals with the same trait in four TLGS phases consistently and at least a family member with the same trait were included and those with obesity (body mass index (BMI) ≥30 kg/m²), cigarette smoking and those receiving drugs affecting HDL-C level were excluded from the study.

Finally, 142 individuals (97 males and 45 females), including 79 individuals with very low HDL-C (59 males and 20 females) and 63 individuals with extreme high HDL-C levels (38 males and 25 females), were eligible and selected from the TLGS participants.

Genetic analysis

After blood sampling, Genomic DNA was isolated from peripheral blood leukocyte using proteinase K, salting-out method. Using specific primers, PCR was performed, and all three exons with at least 100-bp adjacent intronic regions were amplified. In addition to coding regions of APOA2, the regulatory region (promoter) considering at least 500 bp upstream of the transcription start site and 200 bp downstream of transcription start site located in 5′UTR was also amplified. The primer sequences used for the amplification of each APOA2 region are shown in Table 1. Specific primers were designed using Primer3 software (ver. 0.4.0). Four fragments of APOA2 gene were amplified using the following PCR protocols:

- **Promoter**: 94°C, 10 min, 35 cycles (94°C, 50 s; 61.5°C, 45 s; 72°C, 45 s), 72°C, 10 min
- **Exon 1**: 94°C, 10 min, 35 cycles (94°C, 45 s; 52°C, 60 s; 72°C, 30 s), 72°C, 10 min
- **Exon 2**: 95°C, 5 min, 35 cycles (95°C 40 s; 62.5°C, 40 s; 72°C, 33 s), 72°C, 5 min
- **Exon 3**: 94°C, 10 min, 35 cycles (94°C 45 s; 65°C 50 s; 72°C, 30 s), 72°C, 10 min

After DNA amplification, gel electrophoresis was performed on 8% polyacrylamide gel to detect exact PCR product bands. Afterwards, PCR product was sent for DNA sequencing. Direct DNA sequencing was performed using an ABI Prism 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA). The final obtained sequences were aligned by Chromas software (ver. 2.31), and their related electropherograms were viewed and inspected using the same software to identify single nucleotide polymorphisms (SNPs). Powermarker software version 3.25 was used to

| Table 1. PCR primers and related conditions for promoter and all three exons of APOA2 gene |
|-----------------------------------------------|-----------------------------------------------|------------------|------------------|
| Segment | Forward primer (5′ to 3′) | Reverse primer (5′ to 3′) | Product size (bp) |
|---------|--------------------------|--------------------------|------------------|
| Promoter | TTTACACCTGCGCCTTTACC | CCAATGGGCTTCAGCTC | 701 |
| Exon 1  | TGTTGACGACATCGAAGAG | GGTATCCAGCCAGATTTTG | 389 |
| Exon 2  | CAAAGATCTGGCTGGATACC | GTTGGGATCTTTGGGTGAT | 445 |
| Exon 3  | CGATGGGACCAGGCACAGG | ACATACCCAGGCTCAGCTG | 372 |
calculate the allele frequency, linkage disequilibrium (LD), and consistency with Hardy-Weinberg equilibrium for the identified variants\(^\text{[12]}\). The database of Genotypes and Phenotypes (dbGaP)\(^\text{[13]}\) as well as Ensembl Genome Browser\(^\text{[14]}\) were used to identify if any of the detected variants in APOA2 gene are known SNPs and has been reported previously. Exome Variant Server database was also used to assess the functional and clinical significance of identified variants\(^\text{[15]}\). To predict the possible effect of an amino acid change in missense variants on the structure and function of a human protein, polyphen-2 software version 2.2.2\(^\text{[16]}\) was used to remove confounding factors, including age, gender, BMI, and total cholesterol, and then odds ratio (OR) was calculated. \(P\) values \(\leq 0.05\) were considered as significance level. All statistical analyses were carried out using SPSS software version 17.00 for Windows.

### RESULTS

#### Demographics

Due to poor quality of DNA, amplification and sequencing of DNA were carried out only on 77 individuals with extreme low HDL-C levels and 59 of those with extreme high HDL-C levels. Table 2 shows the demographic characteristics of the study participants.

#### Identified variants

After the analysis of all three exons with adjacent intronic regions and the core promoter of APOA2 in individuals with extreme HDL-C levels, nine SNPs and one microsatellite were identified (Table 3), of these variants, five had been previously reported and four were new variants (Fig. 1A and 1B). Also, three of these SNPs had been located in the regulatory (promoter) region, two in the exonic region, three in the intronic region within 100 bps of the intron/exon junction, and one in 3’UTR. The microsatellite of GT repeats was identified in intron 1, 44 bps upstream of exon 2. Two of the identified variants were common variants and others were rare SNPs. Both exonic variants were missense mutation and caused an amino acid change. Table 3 shows the summary of the identified SNPs in APOA2 gene in individuals with extreme HDL-C levels.

![Sequence of a known (A) and new (B) variant in APOA2 sequence. Arrows show the location of variant.](image)

**Fig. 1.** The sequence of a known (A) and new (B) variant in APOA2 sequence. Arrows show the location of variant.

---

Table 2. Demographic characteristics and biochemical parameters of the study participants

| Variable          | Men (mean ± SD) | Women (mean ± SD) | \(P\) value |
|-------------------|-----------------|-------------------|-------------|
| Age (year)        | 40.24±15.61     | 38.71±14.85       | 0.580       |
| HDL-C level (mg/dl)| 43.51±21.02     | 59.58±26.41       | <0.001*     |
| LDL-C level (mg/dl)| 94.77±32.21     | 102.80±35.97      | 0.190       |
| Triglyceride level (mg/dl) | 181.58±18.53 | 116.18±86.69      | <0.001*     |
| Total cholesterol (mg/dl) | 178.67±47.18  | 183.82±49.77      | 0.550       |
| BMI (kg/m\(^2\)) | 25.60±3.51      | 24.92±3.44        | 0.270       |

BMI, body mass index; \(*P<0.05\) significant
Table 3. The identified variants of APOA2 gene in two study groups

| Variant | Allele change | Location                  | Amino acid change | Amino acid position | Polyphen score | Allele frequency | P value |
|---------|---------------|---------------------------|-------------------|---------------------|----------------|------------------|---------|
| 1 rs5082 CR024268 | C>T          | Promoter                  | N/A               | N/A                 |                | 0.617            | 0.0001 |
| 2 rs12721033   | G>C          | Promoter                  | N/A               | N/A                 |                | 0.000            | 0.007  |
| 3 rs72661132   | C>T          | Promoter                  | N/A               | N/A                 |                | 0.000            | 0.007  |
| 4 rs202223831  | C>G          | Exon 1                    | Leu-Val           | 16                  | 0.884          | 0.000            | 0.006  |
| 5 Chr:1:16119396 | G>A          | Intron 1                  | N/A               | N/A                 |                | 0.000            | 0.006  |
| 6 Chr:1:1611929108 | C>G          | Intron 1                  | N/A               | N/A                 |                | 0.000            | 0.006  |
| 7 rs6413453 (CS900228) | C>T          | Intron 2/splice region variant | N/A               | N/A                 |                | 0.100            | 0.088  |
| 8 Chr:1:16119226 | G>C          | Exon 3                    | Ala-Pro           | 98                  | 0.011 (Benign) | 0.036            | 0.000  |
| 9 Chr:1:161192113 | C>G          | 3'UTR                     | N/A               | N/A                 |                | 0.000            | 0.007  |

N/A: not applied
Allele frequency

Table 3 shows the allele frequency of the identified variants in two study groups. The allele frequency of the regulatory variant of rs5082 in the extreme low HDL-C group was significantly higher than that in the extreme high HDL-C group (P = 0.0001). All the identified variants were consistent with Hardy-Weinberg equilibrium. Linkage disequilibrium was observed between all variants that shows common inheritance patterns. Calculation of polyphen score found that one of the two missense variants to be benign and the other one possibly damaging (Table 3).

Associations

There was a significant association between the new missense mutation (variant Chr:1:16119226, Ala98Pro) and the HDL-C level. Mean HDL-C concentration in those with one mutant allele (heterozygote for Ala98Pro-variant) was significantly higher than those with two wild allele (homozygote) (P = 0.034). The frequency of SNP Ala98Pro in high HDL-C group was significantly higher than low HDL-C group (P = 0.024). No significant association was also found between the HDL-C level and two common variants of rs6413453 and rs5082 (P = 0.506 and 0.346, respectively). A multiple logistic regression model was used, and confounding variables, including age, gender, cholesterol level, and BMI were entered to the model but again the association remained non-significant.

DISCUSSION

In genetic screening of all exons and the core promoter of APOA2 in individuals with extreme HDL-C levels, nine variants and one microsatellite were found: Three in the promoter region, two in the coding regions, three in the intronic region adjacent to exons, and one in 3’UTR. Also, the microsatellite of GT repeats was found in the exonic region. A similar study on African Blacks and U.S. Non-Hispanic whites identified 25 variants and one microsatellite in the APOA2 gene[18], which is more than our identified variants.

This study explored APOA2 genetic variants in two groups of extreme HDL-C levels. The study of individuals with extreme HDL-C levels increases the chance of detecting functionally significant rare and common variants with large phenotypic effects[19]. The higher rate of mutation in one extreme group versus the other one is a strong evidence for association between genetic variants and the specific trait[19,20]. By this approach, the common variants seen in both extreme groups with different frequency may have effect on the specific phenotype, whereas rare variants with a strong phenotypic effect are more likely to be found in only one extreme[21].

In this study, the frequency of common variants (rs6413453 and rs5082) was not significantly different between the two HDL-C groups. It seems that these two variants do not affect the HDL-C level. In a study conducted on 88 normolipidemic young men that were given fatty meal, it was found that the carriers of the minor allele of rs5082 (CC/TC) have a lower postprandial response compared with TT homozygotes. Its results indicated that APOA2 rs5082 may decrease the risk of cardiovascular disease due to the lower level of postprandial hypertriglyceridemia[22].

Another study on 556 Australian men with confirmed CAD and 1109 randomly selected healthy individuals showed that there is no significant association between APOA2 rs5082 and the plasma HDL-C levels, which confirms our findings. They also concluded that this variant may be cardioprotective in their population[23]. In another study on 3093 French Caucasian subjects, there was no significant association between rs5082 and rs6413453 with the HDL-C level, which confirms ours. They found a marginally significant association between rs5082 and total cholesterol level as well as between rs6413453 and body weight[24].

In line with our findings, dbGaP and Ensembl Genome Browser indicated that there is not any association between the two variants (rs5082 and rs6413453) and the HDL-C levels[13,14]. In contrast, Hollister[18] reported a significant association between rs6413453 and the HDL-C levels in females.

The present study, for the first time, identified a new missense rare variant (variant Chr:1:16119226, Ala98Pro) that was significantly associated with HDL-C[13,14,24]. The main limitation of the current study was the failure of second APOA2 exon sequencing due to the presence of a long dinucleotide microsatellite of GT repeats in intron 1 and in the upstream of exon 2 that inhibited sequencing and caused incomplete sequencing. (GT)n repetitive sequences are found in the hot spot region of genome and form a left-handed helix structure (Z-DNA). Recombination rate increases in these GT repeated regions (microsatellite)[25]. Two other limitations of the present study are the absence of control group (normal HDL-C levels) as well as the lack of validation and genotyping of the identified variants in a large normal population.

This is a primary screening study, and genotyping of the identified variants will be performed in the next phase of the study by restriction fraction length polymorphism method. Nevertheless, future genotyping studies with a large sample size in a general
population are warranted to validate our study findings. In conclusion, the results do not show any contribution of two common tagging SNPs of rs6413453 and rs5082 in the HDL-C trait in an Iranian population.

ACKNOWLEDGEMENTS

The study was financially supported by the Research Institute for Endocrine Sciences at Shahid Beheshti University of Medical Sciences (Tehran, Iran).

CONFLICT OF INTEREST. None declared.

REFERENCES

1. Kareinen A, Viitanen L, Halonen P, Lehto S, Laakso M. Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary heart disease. Arteriosclerosis, thrombosis, and vascular biology 2001; 21(8): 1346-1352.
2. Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrazadeh H. Prevalence of dyslipidemia in Iran: A systematic review and meta-analysis study. International journal of preventive medicine 2014; 5(4): 373-393.
3. Weisgraber KH, Mahley RW. Apoprotein (E–A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. The journal of biological chemistry 1978; 253(17): 6281-6288.
4. Borghini I, James RW, Blatter MC, Pornetta D. Distribution of apolipoprotein e between free and a-ii complexed forms in very-low- and high-density lipoproteins: Functional implications. Biochimica et biophysica acta 1991; 1083(2): 139-146.
5. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002; 164(1): 1-13.
6. Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, Liu E, Sun H, Waqar AB, Shibata N, Inoue T, Wang Y, Zhang B, Kobayashi J, Morimoto M, Saku K, Watanabe T, Fan J. Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arteriosclerosis, thrombosis, and vascular biology 2009; 29(12): 2047-2053.
7. Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein a-II transgenic mice indicate a role for hdl in adiposity and insulin resistance. Diabetes 2001; 50(3): 643-651.
8. Chan DC, NG TW, Watts GF. Apolipoprotein A-II: Evaluating its significance in dyslipidemia, insulin resistance, and atherosclerosis. Annals of medicine 2012; 44(4): 313-324.
9. Duesing K, Charpentier G, Marre M, Tichet J, Hercberg S, Balkau B, Froguel P, Gibson F. Evaluating the association of common APOA2 variants with type 2 diabetes. BMC medical genetics 2009; 10: 13.
10. Castellani LW, Nguyen CN, Charugundla S, Weinstein MM, Doan CX, Blaner WS, Wongsiriroj N, Lusis LW. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. The journal of biological chemistry 2008; 283(17): 11633-11644.
11. Azizi F, Rahmani M, Emami H, Mirrnan R, Hajipour R, Madjid M, Ghanbili J, Ghanbarian A, Mehrabi Y, Saadat N, Salehi P, Mortazavi N, Haydarian P, Sarbazi N, Allahverdian S, Saadati N, Ainy E, Moeini S. Cardiovascular risk factors in an iranian urban population: Tehran lipid and glucose study (phase 1). Preventive medicine 2002; 47(6): 408-426.
12. Liu KMS. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005; 21(9): 2128-2129.
13. The database of genotypes and phenotypes (dbgap). http://www.ncbi.nlm.nih.gov/books/NBK154410/Ensembl genome browser. http://www.ensembl.org/info/about/publications.html.
14. Davidson WS, Thompson TB. The structure of apolipoprotein a-i in high density lipoproteins. The journal of biological chemistry 2007; 282: 22249-22253.
15. Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacological reviews 1996; 48(2): 289-326.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry 1972; 18(6): 499-502.
17. Hollister SM. Sequence variation in the apoa2 gene and its relationship with plasma hdl-cholesterol levels. Dissertation for Master of Science, University of Pittsburgh, 2008. http://d-scholarship.pitt.edu/7010/.
18. Weisglsas-Volkov D, Pajukanta P. Genetic causes of high and low serum hdl-cholesterol. Journal of lipid research 2010; 51(8): 2032-2057.
19. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Remaley AT, Schnoor P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. The journal of the American medical association 2008; 299(21): 2524-2532.
20. Pajukanta P. Do DNA sequence variants in abca1 contribute to hdl cholesterol levels in the general population? The journal of clinical investigation 2004; 114(9): 1244-1247.
21. Delgado-Lista J, Perez-Jimenez F, Tanaka T, Perez-Martinez P, Jimenez-Gomez Y, Marin C, Ruano J, Parnell L, Ordovas JM, Lopez-Miranda J. An apolipoprotein A-II polymorphism (-265C/T, rs5082) regulates postprandial response to a saturated fat overload in healthy men. The journal of nutrition 2007; 137(9): 2024-2028.
22. Xiao J, Zhang F, Wiltshire S, Hung J, Jennens M,
Beilby JP, Thompson PL, McQuillan BM, McCaskie PA, Carter KW, Palmer LJ, Powell BL. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an australian male population. *Atherosclerosis* 2008; **199**(2): 333-339.

23. Norman JE Jr. Lung cancer mortality in World War I veterans with mustard-gas injury: 1919-1965. *The journal of the national cancer institute* 1975; **54**(2): 311-317.

24. Murray J, Buard J, Neil DL, Yeramian E, Tamaki K, Hollies C, Jeffreys AJ. Comparative sequence analysis of human minisatellites showing meiotic repeat instability. *Genome research* 1999; **9**(2): 130-136.